Highlights: Reduces operating expenses Update on MagSense® HER2 program MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier
MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to report that it
1H2023 Highlights: Achieved enrolment target for Phase I study of MagSense® HER2 breast cancer detection; imaging results corroborated by independent panel of radiologists Announced plan
SINGAPORE, and San Diego, California – Prestige Biopharma, a biopharmaceutical company specializing in innovative antibody therapies, with a strong dedication to tackling pancreatic cancer, and Imagion
Dear Imagion Biosystems Shareholders, It has been an incredible first month ramping up as Chief Executive Officer with Team Imagion Biosystems. With this quarter’s 4C
Highlights include: MagSense® HER2 Phase 1 Study achieves enrolment target Expands collaboration with Siemens Healthineers Dr. Isaac Bright appointed as CEO MELBOURNE – Imagion Biosystems (ASX:IBX),
We’re on a mission to make cancer more detectable.
